Gerhard Hildebrandt, MD, FACP, is a hematologist and oncologist who treats cancers of the blood and lymph system. He joined MU Health Care’s Ellis Fischel Cancer Center to provide the people of mid-Missouri with excellent cancer care, including access to bone marrow transplants, CAR T cell therapy and clinical trials.

When Dr. Hildebrandt meets new patients, he likes to take his time and answer all their questions to ease their fears and help them to process and understand their diagnosis and plan ahead for treatment. The most rewarding part of his work is the bond he builds with patients and their families on the journey to the outcome they all seek, which is a cure.

In his free time, Dr. Hildebrandt enjoys swimming, working out, playing the piano and enjoying the company of his wife, his two daughters, his son and his Labrador retriever Ori.

Education & Training

Medical School

Johannes Gutenberg University Of Mainz-Fachbereich Medizin


Internal Medicine

  • University Hospital Regensburg

Internal Medicine, Hematology & Oncology

  • University Hospital Regensburg


Hematology & Oncology

  • University Hospital Regensburg


MU Health Care participates with most major managed care organizations. To find out whether MU Health Care is a participating provider in your insurance plan or network, or for information on co-payments and deductibles, please contact your insurance carrier directly.

In the News

Academic Information

Director of Ellis Fischel Cancer Center
Chief of the Division of Hematology and Medical Oncology
Nellie B. Smith Endowed Chair of Oncology
NextGen Precision Health Investigator

Research Profile

Dr. Hildebrandt’s laboratory research focuses on complications after bone marrow transplantation, including acute graft-versus-host disease and lung injury. He is exploring how the microbiome of the gut and throat affects immune responses and clinical outcomes after transplants. He is also studying the metabolic pathways that potentially could be targeted in blood cancers and after bone marrow transplants.

NextGen Precision Health

Research Interests

  • Graft-versus-host disease.
  • Impact of the metabolome and microbiome on clinical outcomes in blood cancers and after bone marrow transplantation.

Areas of Expertise

  • Chimeric antigen receptor T (CAR-T) cell therapy.
  • Bone marrow stem cell transplantation.
  • Blood stem cell transplantation.


Dr. Hildebrandt has authored more than 130 peer-reviewed publications and book chapters. He is nationally and internationally known for his accomplishments in the field of bone marrow transplantation and blood cancer care.

Complete list of publications